We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Zevra Therapeutics Inc (ZVRA) USD0.0001

Sell:$4.66 Buy:$4.67 Change: $0.17 (3.79%)
NASDAQ:1.10%
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:$4.66
Buy:$4.67
Change: $0.17 (3.79%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:$4.66
Buy:$4.67
Change: $0.17 (3.79%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

Contact details

Address:
1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION
34747
United States
Telephone:
+1 (321) 9393416
Website:
https://zevra.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZVRA
ISIN:
US4884452065
Market cap:
$195.04 million
Shares in issue:
41.85 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Neil Mcfarlane
    President, Chief Executive Officer, Director
  • R. LaDuane Clifton
    Chief Financial Officer, Treasurer, Secretary
  • Joshua Schafer
    Executive Vice President - Business Development, Chief Commercial Officer
  • Sven Guenther
    Chief Scientific Officer
  • Christal Mickle
    Chief Development Officer
  • Adrian Quartel
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.